EZH2 and acute lymphoblastic leukemia: Therefore, Ikaros exerts an antioncogenic role, mediated through the repression of some targets involved in cell cycle progression (e.g., CDC2 and CDC7), that counteracts EZH2 loss-of-function in BCP-ALL [44].